|Hologic gets FDA nod for cervical cancer screen and StemCells plans another raise|
|By Staff and Wire Reports|
|Thursday, 15 December 2011 20:30|
Medical systems maker Hologic, Inc.(NasdaqGS: HOLX ) said U.S. regulators have approved its device to screen for cervical cancer. The HPV HR test utilizes Hologic's proprietary Invader technology to detect 14 high risk types of HPV that are associated with cervical cancer and precancerous lesions."Our new Cervista high throughput automation system represents a significant addition to our molecular diagnostics product portfolio," said Rob Cascella , President and Chief Executive Officer of Hologic. "The Cervista HTA system automates our Cervista HPV HR test, providing higher throughput, improved chain of custody and accurate results. We are extremely pleased to get this product approved as it materially changes the competitive landscape for Hologic."
"With over 200 U.S. laboratories currently running our Cervista HPV HR test, we have had tremendous success with the early adoption of our manual HPV test," said Rohan Hastie , Vice President and General Manager, Hologic Molecular Diagnostics. "We believe that our success is driven in large part by physician and laboratory confidence in the performance and comprehensive design of the Cervista HPV assays. Having HTA approved quite simply makes us even more competitive."---
StemCells' technology is focused on stem cell discovery that relies upon a library of monoclonal antibodies to human proteins and state of the art cell sorting capabilities. The company uses a library of known and proprietary monoclonal antibodies for identification, purification, and characterization of the human stem cell of interest. It believes that human tissue derived stem cell-based therapy and the use of stem or progenitor cells to treat diseases has the potential to provide a broad therapeutic approach. Its technology of stem cell biology has a wide range of applications including tissue repair and replacement, drug discovery and screening, functional genomics, and correction of genetic disorders.
The company's three most recent financings took place in January 11, 2011 $9.4 million, January 7, 2011 $9.4 million and June 30, 2010 when the company announced an agreement to sell seven million shares of its common stock to Seaside 88, LP a private investment partnership, at a price of $0.865 per share.
Acacia Research Corporation (Nasdaq: ACTG) announced today that its subsidiary, Resonant Biotechnologies LLC, has entered into a settlement agreement with SRU Biosystems, Inc.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of an underwritten public offering of 21,500,000 shares of its common stock, at a price to the public of $10.42 per share.
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2011 fourth quarter and year ended September 30, 2011, on Tuesday, December 20, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Covidien plc (NYSE: COV), a leading global provider of healthcare products, today announced that it plans to spin off its pharmaceuticals business into a standalone public company.
Ecology Coatings, Inc. (OTCQB: ECOC), a leader in the discovery of ultraviolet-curable advanced coatings, today announced that it has developed bio-based GRAS (generally recognized as safe) UV-curable materials for coatings.
Graymark Healthcare, Inc. (NASDAQ: GRMH), the nation's second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), has closed the previously announced agreement to acquire the majority interest in Village Sleep Center in Plano, Texas.
Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) today announced the appointment of Eurosurgical Ltd as the exclusive distributor of the LuViva™ Advanced Cervical Scan in the United Kingdom.
Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it has filed an appeal regarding a preliminary decision of the European Patent Office (EPO) to revoke the company's ANTISENILIN® patents.
MabCure, Inc. (OTCBB:MBCI), a leading developer of antibody based diagnostics and treatments for ovarian, prostate and other cancers today announced that it has recently completed its prospective diagnostic clinical study of 150 patients presenting with pelvic mass.
Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for KALYDECOTM (ivacaftor) and granted the company's request for six-month Priority Review.